Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

What's new in bullous pemphigoid.

Ujiie H, Shibaki A, Nishie W, Shimizu H.

J Dermatol. 2010 Mar;37(3):194-204. doi: 10.1111/j.1346-8138.2009.00792.x. Review.

PMID:
20507382
2.

Human IgG1 monoclonal antibody against human collagen 17 noncollagenous 16A domain induces blisters via complement activation in experimental bullous pemphigoid model.

Li Q, Ujiie H, Shibaki A, Wang G, Moriuchi R, Qiao HJ, Morioka H, Shinkuma S, Natsuga K, Long HA, Nishie W, Shimizu H.

J Immunol. 2010 Dec 15;185(12):7746-55. doi: 10.4049/jimmunol.1000667. Epub 2010 Nov 12.

3.

Antibodies to pathogenic epitopes on type XVII collagen cause skin fragility in a complement-dependent and -independent manner.

Natsuga K, Nishie W, Shinkuma S, Ujiie H, Nishimura M, Sawamura D, Shimizu H.

J Immunol. 2012 Jun 1;188(11):5792-9. doi: 10.4049/jimmunol.1003402. Epub 2012 Apr 20.

4.

Noncollagenous 16A domain of type XVII collagen-reactive CD4+ T cells play a pivotal role in the development of active disease in experimental bullous pemphigoid model.

Ujiie H, Shibaki A, Nishie W, Shinkuma S, Moriuchi R, Qiao H, Shimizu H.

Clin Immunol. 2012 Feb;142(2):167-75. doi: 10.1016/j.clim.2011.10.002. Epub 2011 Oct 17.

PMID:
22044750
5.

Bullous pemphigoid autoantibodies directly induce blister formation without complement activation.

Ujiie H, Sasaoka T, Izumi K, Nishie W, Shinkuma S, Natsuga K, Nakamura H, Shibaki A, Shimizu H.

J Immunol. 2014 Nov 1;193(9):4415-28. doi: 10.4049/jimmunol.1400095. Epub 2014 Sep 26.

6.

A novel active mouse model for bullous pemphigoid targeting humanized pathogenic antigen.

Ujiie H, Shibaki A, Nishie W, Sawamura D, Wang G, Tateishi Y, Li Q, Moriuchi R, Qiao H, Nakamura H, Akiyama M, Shimizu H.

J Immunol. 2010 Feb 15;184(4):2166-74. doi: 10.4049/jimmunol.0903101. Epub 2010 Jan 20.

7.

Anti-collagen XVII single-chain Fv antibody blocks the autoimmune reaction mediated by pathogenic autoantibodies in bullous pemphigoid.

Wu Y, Sun NN, Dang EL, Jin L, Liu ZF, Zhang W, Yang LT, Wang G.

J Dermatol Sci. 2013 Oct;72(1):25-31. doi: 10.1016/j.jdermsci.2013.05.010. Epub 2013 Jun 13.

PMID:
23827201
8.

[Novel animal models for bullous pemphigoid utilized by "humanization of autoantigen"].

Nishie W, Shimizu H.

Nihon Rinsho Meneki Gakkai Kaishi. 2009 Dec;32(6):472-7. Review. Japanese.

9.

Bullous pemphigoid and cicatricial pemphigoid autoantibodies react with ultrastructurally separable epitopes on the BP180 ectodomain: evidence that BP180 spans the lamina lucida.

Bédane C, McMillan JR, Balding SD, Bernard P, Prost C, Bonnetblanc JM, Diaz LA, Eady RA, Giudice GJ.

J Invest Dermatol. 1997 Jun;108(6):901-7.

PMID:
9182819
10.

Mouse models of autoimmune blistering diseases induced by the passive transfer of antibodies.

Nishie W.

Methods Mol Biol. 2013;961:363-9. doi: 10.1007/978-1-62703-227-8_24.

PMID:
23325657
11.

IgE autoantibodies against the intracellular domain of BP180.

Dresow SK, Sitaru C, Recke A, Oostingh GJ, Zillikens D, Gibbs BF.

Br J Dermatol. 2009 Feb;160(2):429-32. doi: 10.1111/j.1365-2133.2008.08858.x. Epub 2008 Sep 19.

PMID:
18808416
13.

Granulocyte-derived elastase and gelatinase B are required for dermal-epidermal separation induced by autoantibodies from patients with epidermolysis bullosa acquisita and bullous pemphigoid.

Shimanovich I, Mihai S, Oostingh GJ, Ilenchuk TT, Bröcker EB, Opdenakker G, Zillikens D, Sitaru C.

J Pathol. 2004 Dec;204(5):519-27.

PMID:
15538734
14.

The pathophysiology of bullous pemphigoid.

Kasperkiewicz M, Zillikens D.

Clin Rev Allergy Immunol. 2007 Oct;33(1-2):67-77. Review.

PMID:
18094948
15.

Pathogenesis of bullous pemphigoid.

Ujiie H, Nishie W, Shimizu H.

Immunol Allergy Clin North Am. 2012 May;32(2):207-15, v. doi: 10.1016/j.iac.2012.04.001. Epub 2012 Apr 17.

PMID:
22560134
16.

Clinical manifestations in 100 Japanese bullous pemphigoid cases in relation to autoantigen profiles.

Tanaka M, Hashimoto T, Dykes PJ, Nishikawa T.

Clin Exp Dermatol. 1996 Jan;21(1):23-7.

PMID:
8689764
17.

Update on the pathogenesis of bullous pemphigoid: an autoantibody-mediated blistering disease targeting collagen XVII.

Nishie W.

J Dermatol Sci. 2014 Mar;73(3):179-86. doi: 10.1016/j.jdermsci.2013.12.001. Epub 2013 Dec 27. Review.

PMID:
24434029
18.

Repetitive immunization breaks tolerance to type XVII collagen and leads to bullous pemphigoid in mice.

Hirose M, Recke A, Beckmann T, Shimizu A, Ishiko A, Bieber K, Westermann J, Zillikens D, Schmidt E, Ludwig RJ.

J Immunol. 2011 Aug 1;187(3):1176-83. doi: 10.4049/jimmunol.1100596. Epub 2011 Jun 24.

20.

Role of FcRs in animal model of autoimmune bullous pemphigoid.

Zhao M, Trimbeger ME, Li N, Diaz LA, Shapiro SD, Liu Z.

J Immunol. 2006 Sep 1;177(5):3398-405.

Supplemental Content

Support Center